image
Healthcare - Biotechnology - NASDAQ - CA
$ 3.98
-0.756 %
$ 143 M
Market Cap
-5.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one EPRX stock under the worst case scenario is HIDDEN Compared to the current market price of 3.98 USD, Eupraxia Pharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one EPRX stock under the base case scenario is HIDDEN Compared to the current market price of 3.98 USD, Eupraxia Pharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one EPRX stock under the best case scenario is HIDDEN Compared to the current market price of 3.98 USD, Eupraxia Pharmaceuticals Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EPRX

image
$4.4$4.4$4.2$4.2$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.0$2.8$2.815 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-37.2 M OPERATING INCOME
-64.33%
-25.7 M NET INCOME
31.15%
-30 M OPERATING CASH FLOW
-7.44%
-75.2 K INVESTING CASH FLOW
24.11%
45.8 M FINANCING CASH FLOW
64.44%
0 REVENUE
0.00%
-7.12 M OPERATING INCOME
4.78%
-6.77 M NET INCOME
10.16%
-6 M OPERATING CASH FLOW
-0.51%
-169 K INVESTING CASH FLOW
-286.32%
430 K FINANCING CASH FLOW
-98.65%
Balance Sheet Eupraxia Pharmaceuticals Inc.
image
Current Assets 34.4 M
Cash & Short-Term Investments 33.1 M
Receivables 229 K
Other Current Assets 1.11 M
Non-Current Assets 506 K
Long-Term Investments 0
PP&E 425 K
Other Non-Current Assets 80.8 K
94.73 %3.17 %Total Assets$34.9m
Current Liabilities 3.1 M
Accounts Payable 0
Short-Term Debt 71.9 K
Other Current Liabilities 3.03 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
97.68 %Total Liabilities$3.1m
EFFICIENCY
Earnings Waterfall Eupraxia Pharmaceuticals Inc.
image
Revenue 0
Cost Of Revenue 210 K
Gross Profit -210 K
Operating Expenses 37.2 M
Operating Income -37.2 M
Other Expenses -11.5 M
Net Income -25.7 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)0(210k)(210k)(37m)(37m)11m(26m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Eupraxia Pharmaceuticals Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -25.7 M
Depreciation & Amortization 172 K
Capital Expenditures -104 K
Stock-Based Compensation 3.22 M
Change in Working Capital -6.76 M
Others -6.83 M
Free Cash Flow -30.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Eupraxia Pharmaceuticals Inc.
image
EPRX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Eupraxia Pharmaceuticals Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 2, 2025. Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company's board of directors (the “Board”) at the Meeting and listed in the Company's Management Information Circular dated April 25, 2025, were elected. globenewswire.com - 2 weeks ago
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) globenewswire.com - 1 month ago
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) globenewswire.com - 1 month ago
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company's management and scientific teams will present at the following investor and scientific conferences in April and May: Osteoarthritis Research Society International World Congress April 24-27, 2025 Dr. Phil Conaghan, a member of the Company's OA Clinical Advisory Board, will be presenting a poster on the Company's behalf at the Osteoarthritis Research Society International (“OARSI”) World Congress 2025, being held April 24-27, 2025 in Incheon (Seoul), South Korea. Poster Details Poster Title: EP-104IAR (extended-release intra-articular injection of fluticasone propionate) shows sustained pain response for subjects with moderate baseline pain and BMI less than 30 in SPRINGBOARD, a Phase 2, randomized, 24-week study of osteoarthritis of the knee. globenewswire.com - 1 month ago
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results VICTORIA, BC , March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. prnewswire.com - 3 months ago
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase Cohort 6 showed the greatest symptom relief scores ("SDI") of all cohorts to date at 12 weeks Cohort 6 had the greatest magnitude and percentage change in tissue health scores ("EoEHSS") of any cohort to date at 12 weeks Cohort 6 saw the greatest reduction in Peak Eosinophil Count ("PEC") of any cohort to date Cohort 5 demonstrated the greatest symptom score reduction (SDI) seen to date at 24 weeks, showing continuously improving symptom relief over that time For tissue health (EoEHSS) and PEC there is a clear dose-response from Cohorts 3 to 6, with Cohort 6 showing the greatest response No serious adverse events nor any events of oral or gastrointestinal candidiasis were reported in any of the six cohorts Cohort 7 is fully enrolled, with 12-week data expected in Q2 2025 Company to host Webinar to discuss data from RESOLVE trial on Wednesday, February 26 th at 11:00am PT (Link to Webinar) VICTORIA, BC , Feb. 25, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in precision local drug delivery, today announced additional positive clinical data from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE"). EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. prnewswire.com - 3 months ago
Eupraxia Pharmaceuticals Announces CFO Succession -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC , Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. prnewswire.com - 4 months ago
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months DiffuSphere™ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing systemic drug levels to optimize safety In clinical trials, a single administration of DiffuSphere™ successfully delivered fluticasone propionate for at least six months in patients with eosinophilic esophagitis or osteoarthritis DiffuSphere™ has shown its versatility with various drug classes, supporting the possibility to treat multiple types of pain, infectious diseases, eye diseases and cancers VICTORIA, BC , Nov. 20, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today unveiled new pharmacokinetic ("PK") data from its Phase 2a Eosinophilic Esophagitis ("EoE") program. Management believes these data underscore the unique capabilities of Eupraxia's proprietary DiffuSphere™ platform technology, which aims to provide precise, localized, safe, and effective long-lasting drug delivery. prnewswire.com - 6 months ago
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting VICTORIA, BC , Nov. 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a poster at the American College of Rheumatology (the "ACR") Convergence 2024 Annual Meeting, being held in Washington, D.C. from November 14-19, 2024. prnewswire.com - 7 months ago
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence Registration for the webinar now open to the public by visiting EPRXNOV1524.TribePublic.com VICTORIA, BC , Nov. 13, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that Eupraxia's CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar Presentation and Q&A Event titled, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed". prnewswire.com - 7 months ago
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks. prnewswire.com - 7 months ago
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results VICTORIA, BC , Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the third quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. prnewswire.com - 7 months ago
8. Profile Summary

Eupraxia Pharmaceuticals Inc. EPRX

image
COUNTRY CA
INDUSTRY Biotechnology
MARKET CAP $ 143 M
Dividend Yield 0.00%
Description Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Contact 2067 Cadboro Bay Road, Victoria, BC, V8R 5G4 https://www.eupraxiapharma.com
IPO Date None
Employees 33
Officers Dr. James A. Helliwell FRCPC, M.D. Chief Executive Officer & Director Dr. Amanda Malone Ph.D. Chief Scientific Officer & Chief Operating Officer Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Business Officer Dr. Mark M. Kowalski M.D., Ph.D. Chief Medical Officer Mr. Alexander John Rothwell Eng., M.B.A. Chief Financial Officer